Overview

Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels. On average, increasing the PRA from 0 to 50% specifically in the Washington Organ Procurement Organization (OPO) increases the waiting time from 3 to 6 years. Spontaneous decreases in the PRA rarely occur and is associated with a decreased chance for transplantation and a decreased rate of survival.

Phase:

Phase 2

Details

Lead Sponsor:

University of Washington

Collaborator:

Hoffmann-La Roche

Treatments:

Antibodies
Immunoglobulins
Mycophenolate mofetil
Mycophenolic Acid